Forte Biosciences, Inc. (FBRX) Form 8-K — Jul 27, 2026
Forte Biosciences entered into a definitive agreement to be acquired by argenx BV for $77.00 per share in cash, representing a total transaction value of approximately $1.58 billion based on outstanding shares. The transaction will be structured as a two-step process, commencing with a tender offer within 10 business days, followed by a second-step merger under Delaware law. The Company's board of directors unanimously approved the transaction and recommended that stockholders tender their shares. All outstanding stock options and restricted stock units will vest and convert into the right to receive a cash payment equal to the merger consideration, subject to withholding taxes.
Key figures
- Offer Price
- 77
- Termination Fee
- 65000000
- Shares Outstanding
- 20489993
- Drop dead date
- 2026-11-30
- Tender offer min days
- 15
- Minimum tender condition
- >50%
Price after filing
Close on the filing date to close N calendar days later (from $76.50). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.